SCHEMBL3015894

SCHEMBL3015894

O=S(=O)(c1cc(Cl)cc(Cl)c1)C1CCN(c2nc(Cc3ccc(Cl)c(F)c3)cs2)CC1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.35
PROKR1 Q8TCW9 3/20 0.35
FPR2 P25090 2/20 0.35
DRD2 P14416 1/20 0.35
HTR2A P28223 1/20 0.35
HTR2C P28335 1/20 0.35
KCNH2 Q12809 1/20 0.35
SLC13A5 Q86YT5 1/20 0.34
SMN1; SMN2 Q16637 4/20 0.33
RAB9A P51151 2/20 0.33
ITGB1 P05556 1/20 0.33
ITGA4 P13612 1/20 0.33
NPC1 O15118 1/20 0.33
CACNA1G O43497 1/20 0.33
CACNA1H O95180 1/20 0.33
CACNA1I Q9P0X4 1/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
HRH3 Q9Y5N1 1/20 0.33
ALDH1A1 P00352 1/20 0.33
DRD4 P21917 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3011752 0.94 CACNA1G (0.38) MAPTDRD2HTR2AHTR2CKCNH2
SCHEMBL3011420 0.94 HTR2A (0.42) MAPTPROKR1FPR2DRD2HTR2A
SCHEMBL3017605 0.93 MAPT (0.35) MAPTDRD2HTR2AHTR2CKCNH2
SCHEMBL3013571 0.93 RAB9A (0.38) MAPTPROKR1FPR2DRD2HTR2A
SCHEMBL3004485 0.93 HTR2A (0.36) MAPTPROKR1FPR2DRD2HTR2A
SCHEMBL3014833 0.92 L3MBTL1 (0.35) MAPTPROKR1FPR2DRD2HTR2A
SCHEMBL3007239 0.92 HTR2A (0.40) MAPTPROKR1FPR2DRD2HTR2A
SCHEMBL3009908 0.91 LMNA (0.38) MAPTPROKR1FPR2HTR2ASLC13A5
SCHEMBL3010530 0.90 HTR2A (0.35) MAPTPROKR1FPR2DRD2HTR2A
SCHEMBL3017935 0.90 HTR2A (0.35) MAPTPROKR1FPR2DRD2HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885PROKR1 2080/4885FPR2 3310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.